Capital Advisors Ltd. LLC Sells 157 Shares of Icon Plc $ICLR

Capital Advisors Ltd. LLC cut its holdings in Icon Plc (NASDAQ:ICLR) by 33.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 314 shares of the medical research company’s stock after selling 157 shares during the period. Capital Advisors Ltd. LLC’s holdings in Icon were worth $46,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Ninety One UK Ltd increased its holdings in shares of Icon by 2.6% in the 2nd quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company’s stock worth $435,427,000 after buying an additional 75,465 shares during the last quarter. Ninety One North America Inc. grew its holdings in Icon by 20.5% during the 2nd quarter. Ninety One North America Inc. now owns 428,851 shares of the medical research company’s stock valued at $62,376,000 after purchasing an additional 72,945 shares during the last quarter. Canoe Financial LP grew its holdings in Icon by 10.3% during the 2nd quarter. Canoe Financial LP now owns 193,851 shares of the medical research company’s stock valued at $28,196,000 after purchasing an additional 18,174 shares during the last quarter. Running Oak Capital LLC grew its holdings in Icon by 29.2% during the 2nd quarter. Running Oak Capital LLC now owns 107,218 shares of the medical research company’s stock valued at $15,595,000 after purchasing an additional 24,260 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS grew its holdings in Icon by 2.6% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 99,627 shares of the medical research company’s stock valued at $17,434,000 after purchasing an additional 2,525 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Icon Price Performance

Shares of ICLR opened at $187.71 on Friday. The company has a 50 day moving average price of $174.22 and a 200-day moving average price of $156.99. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $303.69. The stock has a market capitalization of $15.16 billion, a PE ratio of 19.31, a PEG ratio of 2.77 and a beta of 1.23. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.08. Icon had a net margin of 9.82% and a return on equity of 10.95%. The company had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the prior year, the company posted $3.75 earnings per share. Icon’s revenue for the quarter was down 4.8% compared to the same quarter last year. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. Equities analysts predict that Icon Plc will post 13.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Jefferies Financial Group downgraded shares of Icon from a “buy” rating to a “hold” rating and cut their price target for the company from $220.00 to $175.00 in a report on Tuesday, September 9th. Baird R W upgraded shares of Icon from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a report on Wednesday. Rothschild & Co Redburn raised shares of Icon from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $184.00 to $236.00 in a research report on Wednesday, September 3rd. Finally, UBS Group boosted their price objective on shares of Icon from $170.00 to $240.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $217.33.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.